NCT06022250View on ClinicalTrials.gov

The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of JS207 in Patients With Advanced Malignant Tumor

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

98

Participants

Timeline

Start Date

September 26, 2023

Primary Completion Date

December 31, 2025

Study Completion Date

June 30, 2026

Conditions
Advanced Malignant Tumor
Interventions
DRUG

JS207

Patients will receive specific dose of JS207 via intravenous infusion.

Trial Locations (1)

250117

Affiliated Cancer Hospital of Shandong First Medical University, Jinan

All Listed Sponsors
collaborator

Sponsor GmbH

OTHER

lead

Shanghai Junshi Bioscience Co., Ltd.

OTHER

NCT06022250 - The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of JS207 in Patients With Advanced Malignant Tumor | Biotech Hunter | Biotech Hunter